The availability of these gene delivery technologies, such as Ad-based gene expression technology would pave ways to overexpress or knockdown targeted genes such as maternally expressed gene 3 (MEG3) to generate a therapeutic effect in glioma. This evidence concerns the gene MEG3 and glioma.